Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kwang Je Lee, Jae-Kean Ryu, Yun-Hyeong Cho, Won Yong Shin, Jeong Su Kim, Young Won Yoon, Ji Yong Jang, Won Ho Kim, Jong Wook Beom & Seok-Min Kang. (2023) Effectiveness and Safety of a Fixed-Dose Combination of Valsartan and Rosuvastatin (Rovatitan® Tablet) in Patients with Concomitant Hypertension and Hyperlipidemia: An Observational Study. Drug Design, Development and Therapy 17, pages 1047-1062.
Read now
Read now
Articles from other publishers (21)
Hany A. Batakoushy, Zeinab Adel Nasr, Marwa M. Soliman, Sona S. Barghash, Fatma A. Fouad & Aya Barseem. (2023) A novel sustainable second‐derivative synchronous spectrofluorimetric method for the simultaneous determination of olmesartan medoxomil and rosuvastatin calcium in bulk and formulations: Integrated greenness and whiteness evaluation. Luminescence.
Crossref
Crossref
Hussam Al Hennawi, Muhammad Talal Ashraf, Muhammad Zohaib, Muhammad Khuzzaim Khan, Ibrahim Ahmed Khan, Hamza Zahid Ullah Muhammadzai, Rahat Ahmed Memon, Usama Sadiq, Ali Siddiqi, Sohaib Roomi & Abhinav Nair. (2023) Polypill Therapy in Cardiovascular Disease: A Meta-Analysis of Randomized Controlled Trials. Current Problems in Cardiology 48:8, pages 101735.
Crossref
Crossref
Stefania Angela Di Fusco, Stefano Aquilani, Antonella Spinelli, Alessandro Alonzo, Andrea Matteucci, Lorenzo Castello, Giuseppe Imperoli & Furio Colivicchi. (2023) The polypill strategy in cardiovascular disease prevention: It's time for its implementation. Progress in Cardiovascular Diseases 79, pages 37-40.
Crossref
Crossref
Hui Ting Liu, Nian Hua Deng, Ze Fan Wu, Zhan Yang Zhou, Zhen Tian, Xi Yan Liu, Yan Xia Wang, Hong Yu Zheng, Yang Shao Ou & Zhi Sheng Jiang. (2023) Statin's role on blood pressure levels: Meta‐analysis based on randomized controlled trials. The Journal of Clinical Hypertension 25:3, pages 238-250.
Crossref
Crossref
Abdelrahman I. Abushouk, Ahmed Sayed, Malak Munir, Esraa Ghanem, Omar Abdelfattah, Erin D. Michos, Amgad Mentias, Samir Kapadia & Steven E. Nissen. (2022) Fixed-Dose Combination (Polypill) for Cardiovascular Disease Prevention: A Meta-Analysis. American Journal of Preventive Medicine 63:3, pages 440-449.
Crossref
Crossref
Jianwu Lu, Xiao Li, Shun Yuan, Yinquan Wang, Han Sun, Weizhao Weng, Yinfei Shi, Xiaoxu Wang, Kongcheng Huang, Xun Sun & Taizhi Wu. (2022) Identification, Synthesis, and Comprehension of an Imidazole N-3 Regioisomeric Impurity of Olmesartan Medoxomil Key Intermediate. Organic Process Research & Development 26:4, pages 1247-1257.
Crossref
Crossref
Omneya A. Kandil, Karam R. Motawea, Merna M. Aboelenein & Jaffer Shah. (2022) Polypills for Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Sang-Ho Jo, Seok Min Kang, Byung Su Yoo, Young Soo Lee, Ho Joong Youn, Kyungwan Min, Jae Myung Yu, Hyun Ju Yoon, Woo Shik Kim, Gee Hee Kim, Jae Hyoung Park, Seok Yeon Kim & Cheol Ho Kim. (2022) A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study. Journal of Clinical Medicine 11:2, pages 350.
Crossref
Crossref
Ioannis Bellos, Vasilios Pergialiotis & Despina N. Perrea. (2021) Comparative efficacy of fixed-dose statin and antihypertensive agent combinations: A network meta-analysis of randomized controlled trials. Vascular Pharmacology 141, pages 106900.
Crossref
Crossref
Sungjae Lee, Seungwon Yang & Min Jung Chang. (2021) Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies. PLOS ONE 16:11, pages e0260391.
Crossref
Crossref
Areti Sofogianni & Konstantinos Tziomalos. (2020) Fixed‐dose combinations of lipid‐lowering and antihypertensive agents: The way forward?. The Journal of Clinical Hypertension 22:2, pages 270-272.
Crossref
Crossref
Hyoeun Kim, Chan Joo Lee, Donghoon Choi, Byeong-Keuk Kim, In-Cheol Kim, Jung-Sun Kim, Chul-Min Ahn, Geu-Ru Hong, In-Jeong Cho, Chi-Young Shim & Sang-Hak Lee. (2020) Lipid-Lowering Efficacy and Safety of a New Generic Rosuvastatin in Koreans: an 8-Week Randomized Comparative Study with a Proprietary Rosuvastatin. Journal of Lipid and Atherosclerosis 9:2, pages 283.
Crossref
Crossref
Raju KanukulaHariprasad EsamJohan SundströmAnthony Rodgers & Abdul Salam. (2019) Does Co-administration of Antihypertensive Drugs and Statins Alter Their Efficacy and Safety? A Systematic Review and Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology 73:6, pages 352-358.
Crossref
Crossref
Tae-Seok Kim, Seung-Woon Rha, Seok-Yeon Kim, Dae-Gyun Park, Ki-Chul Sung, Myung-Ho Yoon, Kye-Hoon Kim, Han-Cheol Lee, Woo-Sik Kim, Yong-Jin Kim, Jeong-Cheon Ahn, Moo-Yong Rhee, Dong-Hun Cha, Byung-Su Yoo, Sang-Ho Park, Ki-Dong Yoo, Dong-Woon Jeon, Young-Won Yoon, Sang-Kyoon Cho & Yong-Seog Oh. (2019) Efficacy and Tolerability of Telmisartan/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind Study. Clinical Therapeutics 41:4, pages 728-741.
Crossref
Crossref
Álvaro Sosa-Liprandi, María Inés Sosa Liprandi, Erick Alexánderson, Álvaro Avezum, Fernando Lanas, José Patricio López-Jaramillo, Felipe Martínez, Carlos I. Ponte-Negretti N, Fernando Wyss, José Ramón González Juanatey & Pablo Perel. (2019) Clinical Impact of the Polypill for Cardiovascular Prevention in Latin
America: A Consensus Statement of the Inter-American Society of
Cardiology. Global Heart 14:1, pages 3.
Crossref
Crossref
Dan DuBourdieu. 2019. Nutraceuticals in Veterinary Medicine. Nutraceuticals in Veterinary Medicine
765
774
.
Jimin Lee & Sukhyang Lee. (2018)
Comparative Effectiveness of Combination Therapy with Statins and Angiotensin‐Converting Enzyme Inhibitors versus Angiotensin
II
Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population‐Based Cohort Study in Korea
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:11, pages 1095-1105.
Crossref
Crossref
Gyu Chul Oh, Jung-Kyu Han, Ki Hoon Han, Min-Su Hyon, Joon Hyung Doh, Moo Hyun Kim, Jin-Ok Jeong, Jang-Ho Bae, Sang Hyun Kim, Byung-Su Yoo, Sang Hong Baek, Moo-Yong Rhee, Sang-Hyun Ihm, Jung Hoon Sung, Young Jin Choi, Soo-Joong Kim, Kyung-Soon Hong, Byoung Kwon Lee, JangHyun Cho, Eun Seok Shin, Jay Young Rhew, Hyunsu Kim & Hyo-Soo Kim. (2018) Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study. Clinical Therapeutics 40:5, pages 676-691.e1.
Crossref
Crossref
Ehete Bahiru, Angharad N de Cates, Matthew RB Farr, Morag C Jarvis, Mohan Palla, Karen Rees, Shah Ebrahim & Mark D Huffman. (2017) Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database of Systematic Reviews 2017:3.
Crossref
Crossref
Mark D Huffman, Denis Xavier & Pablo Perel. (2017) Uses of polypills for cardiovascular disease and evidence to date. The Lancet 389:10073, pages 1055-1065.
Crossref
Crossref
Cheol Moon & Euichaul Oh. (2016) Rationale and strategies for formulation development of oral fixed dose combination drug products. Journal of Pharmaceutical Investigation 46:7, pages 615-631.
Crossref
Crossref